Carisma Therapeutics and Sesen Bio merger draws opposition from large shareholder


The Sesen Bio investor group calls the Carisma merger proposal a "illogical, value-destructive transaction."

Previous These were the six biggest Massachusetts health care stories of 2022
Next French bistro closed in Chapel Hill, revived as new concept from 'Top Chef' alum